Lineage Cell Therapeutics (LCTX) Cash from Investing Activities (2010 - 2026)

Lineage Cell Therapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$2.3 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 222.23% year-over-year to -$2.3 million; the TTM figure through Mar 2026 stood at -$17.7 million (down 4719.07% YoY), while the FY2025 annual figure was -$13.5 million, down 483.06% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$2.3 million, up from -$15.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $19.2 million in Q2 2023, with the low at -$40.9 million in Q3 2022.
• The 5-year median for Cash from Investing Activities is -$14000.0 (2025), against an average of -$1.0 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities plunged 60067.65% in 2022, then jumped 33634.78% in 2023.
• Lineage Cell Therapeutics' Cash from Investing Activities stood at -$5.1 million in 2022, then jumped by 290.94% to $9.7 million in 2023, then plunged by 72.95% to $2.6 million in 2024, then slumped by 681.94% to -$15.3 million in 2025, then soared by 84.83% to -$2.3 million in 2026.
• Business Quant data shows LCTX's Cash from Investing Activities at -$2.3 million in Q1 2026, -$15.3 million in Q4 2025, and -$12000.0 in Q3 2025.